Stay updated with breaking news from Nasdaq Grph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Research analysts at SVB Leerink upped their Q1 2023 EPS estimates for shares of Graphite Bio in a research report issued on Monday, March 20th. SVB Leerink analyst M. Foroohar now expects that the company will post earnings per share of ($0.13) for the quarter, up from […]
Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Equities researchers at Cantor Fitzgerald issued their FY2022 earnings estimates for Graphite Bio in a report issued on Thursday, September 15th. Cantor Fitzgerald analyst O. Brayer forecasts that the company will post earnings per share of ($1.45) for the year. Cantor Fitzgerald currently has a “Overweight” rating […]
Graphite Bio (NASDAQ:GRPH – Get Rating) and Cellectis (NASDAQ:CLLS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Valuation and Earnings This table compares Graphite Bio and Cellectis’ […]
Graphite Bio (NASDAQ:GRPH – Get Rating) is one of 262 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Graphite Bio to related companies based on the strength of its institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability. Valuation and Earnings This […]
Graphite Bio (NASDAQ:GRPH – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, “Graphite Bio Inc. is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc. is […]